Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Melanoma
- Melanoma Stage III
- Melanoma Stage IV
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Trial design updated from randomised allocation of patients to physician's choice as per version 2.2 of protocol, there will be a pre-specified number of patients with stage IV M1c disease in each arm (approximately 60%).Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03161756
- Collaborators
- Peter MacCallum Cancer Centre, Australia
- Amgen
- Bristol-Myers Squibb
- Investigators
- Study Chair: A/Prof Shahneen Sandhu Peter MacCallum Cancer Centre, Australia Study Chair: Prof. Grant McArthur Peter MacCallum Cancer Centre, Australia